Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04287790 · ClinicalTrials.gov registry record
Promoting Medications for Alcohol Use Disorder on the General Medicine Service
A clinical trial, sponsored by Yale University.
- Terminated
- Registry status
- 67
- Enrollment target
NCT04287790: Clinical Trial study, sponsored by Yale University.
NCT04287790 is a clinical trial that was terminated before completion, run by Yale University. The registered enrollment target is 67 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04287790 was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- 67 participants
- Enrollment target
Study Summary
Medications for Alcohol use disorder (MAUD) (acamprosate, naltrexone, and disulfiram) remain underutilized despite guideline recommendations and rising alcohol-related morbidity and mortality. Alcohol use disorder (AUD)-related hospitalizations are opportunities to initiate MAUD, but optimal implementation strategies are unclear. We will complete a 6 month pilot implementation intervention involving audit and feedback, educational meetings, and academic detailing for health professionals at Yale New Haven Hospital to determine the impact on: 1) health professional satisfaction with intervention components, 2) health professional knowledge and attitudes about medications for alcohol use disorder, 3) receipt of medication among hospitalized patients diagnosed with an alcohol use disorder and 4) 30 day readmission among hospitalized patients with alcohol use disorder. Health professional satisfaction and knowledge with be assessed using a pre-post design and receipt of medications and 30 day readmission will be assessed using a interrupted time series design. We hypothesize health professional knowledge and attitudes about MAUD will be greater after the pilot intervention compared to before. We hypothesize receipt of MAUD will be greater after the pilot intervention compared to before. We hypothesize 30 day readmission will be less after the pilot intervention compared to before.
Primary Outcome
receipt of medication among hospitalized patients diagnosed with an alcohol use disorder (patients discharged from the general medicine service at Yale New Haven Hospital York street campus following hospitalization for an alcohol related diagnosis) The primary outcome, receipt of medication, can occur with any of four events: 1. Administration of intramuscular naltrexone during hospitalization (Y/N) 2. Discharge outpatient prescription of acamprosate (Y/N) 3. Discharge outpatient prescription
Interventions
- BEHAVIORAL audit and feedback, educational meetings, and academic detailing to promote medication receipt
- DRUG Acamprosate, naltrexone, or disulfiram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2021-02-01 |
Why NCT04287790 stopped before completion
NCT04287790 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 67 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which audit and feedback, educational meetings, and academic detailing to promote medication receipt is the first listed.
NCT04287790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04287790 about?
NCT04287790 is a clinical study titled "Promoting Medications for Alcohol Use Disorder on the General Medicine Service". Medications for Alcohol use disorder (MAUD) (acamprosate, naltrexone, and disulfiram) remain underutilized despite guideline recommendations and rising alcohol-related morbidity and mortality. Alcohol use disorder (AUD)-related hospitalizations are opportunities to initiate MAUD, but optimal impleme...
What is the current status of trial NCT04287790?
This trial is currently terminated. The enrollment target is 67 participants. The study started on 2020-01-01. Estimated completion is 2021-02-01.
What interventions are being tested in trial NCT04287790?
The interventions under investigation include: audit and feedback, educational meetings, and academic detailing to promote medication receipt (BEHAVIORAL), Acamprosate, naltrexone, or disulfiram (DRUG).
Who is sponsoring clinical trial NCT04287790?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI